Pre-made Ravagalimab benchmark antibody ( Whole mAb, anti-CD40 therapeutic antibody, Anti-p50/Bp50/CDW40/TNFRSF5 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-471
Pre-Made Ravagalimab biosimilar, Whole mAb, Anti-CD40 Antibody: Anti-p50/Bp50/CDW40/TNFRSF5 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ravagalimab (formerly ABBV 323), a CD40 antagonist biologic, is being developed by AbbVie, for the treatment of ulcerative colitis and Sjogren's syndrome.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Ravagalimab biosimilar, Whole mAb, Anti-CD40 Antibody: Anti-p50/Bp50/CDW40/TNFRSF5 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||6pe7:HL/6pe8:HL:AB|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Active||Ulcerative colitis;Sjogren's syndrome|
|Conditions Discontinued||Crohn's disease|